Amneal Pharmaceuticals Inc Class A (AMRX) financials
Amneal Pharmaceuticals revenue and earnings by year
Amneal Pharmaceuticals's revenue was $3.02 billion in the fiscal year to December 31, 2025, up 8.0% from the year before. Net income was $72.1 million, 2.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 12.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.02 | 2.79 | 2.39 | 2.21 | 2.09 | 1.99 | 1.63 | 1.66 | 1.03 | 1.02 |
| Revenue growth | 8.0% | 16.7% | 8.2% | 5.7% | 5.1% | 22.5% | -2.2% | 60.9% | 1.5% | — |
| Gross profit | 1.11 | 1.02 | 0.82 | 0.78 | 0.77 | 0.63 | 0.35 | 0.72 | 0.53 | 0.60 |
| Gross margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | 31.5% | 21.7% | 43.1% | 50.9% | 58.7% |
| Operating income | 0.39 | 0.25 | 0.20 | -0.09 | 0.15 | 0.09 | -0.25 | -0.02 | 0.25 | 0.28 |
| Operating margin | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% | 23.7% | 28.0% |
| Net income | 0.07 | -0.12 | -0.08 | -0.13 | 0.01 | 0.09 | -0.36 | -0.02 | 0.00 | 0.00 |
| Net margin | 2.4% | -4.2% | -3.5% | -5.9% | 0.5% | 4.6% | -22.3% | -1.3% | 0.0% | 0.0% |
| Diluted EPS | $0.22 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.61 | -$2.76 | -$0.17 | $0.00 | — |
| Free cash flow | 0.24 | 0.23 | 0.30 | 0.02 | 0.19 | 0.32 | -0.05 | 0.19 | 0.14 | -0.01 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AMRX in Markets.
How Amneal Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Affordable Medicines | $490M | 61.5% |
| Av KARE | $157M | 19.7% |
| Specialty | $149M | 18.8% |
See also: AMRX valuation and P/E history · AMRX returns
No forecast, no recommendation. This page describes Amneal Pharmaceuticals Inc Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.